Carl L. Gordon - 06 Aug 2026 Form 4 Insider Report for BlossomHill Therapeutics, Inc. (BLSM)

Reporting relationship: Director
Issuer ticker: BLSM
Reported as of: 06 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Aug 2026, 18:33:43 UTC
Prior SEC filing: 23 Jul 2026
Next SEC filing: 12 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Vincent Liptak, Attorney-in-Fact

Key filing fact

Carl L. Gordon filed Form 4 for BlossomHill Therapeutics, Inc. (BLSM) on 10 Aug 2026.

Key facts

This page summarizes Carl L. Gordon's Form 4 filing for BlossomHill Therapeutics, Inc. (BLSM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Aug 2026, 18:33.

Change

Previous filing in this sequence was filed on 23 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001282930 Primary reporting owner

GORDON CARL L

Relationship: Director
Address: C/O BLOSSOMHILL THERAPEUTICS, INC., 10255 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO
Signature: /s/ Vincent Liptak, Attorney-in-Fact
Signature date: 10 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLSM transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
Shares: +23,904
Change %
Price: $0.000000^*
Shares after: 23,904
Date: 06 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,904
Exercise price: $16.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.

Footnote F2

Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.